Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Mooij

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Science (New York, N.Y.)|February 26, 2005
Physics. The road to quantum computingHans Mooij
Hepatology (Baltimore, Md.)|January 12, 2012
Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemiaH Carlijne Hassing, Hans Mooij, Shuling Guo, et al.
Haematologica|November 2, 2018
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE studyAnton Hagenbeek, Hans Mooij, Josée Zijlstra, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Science (New York, N.Y.)|February 26, 2005
Physics. The road to quantum computingHans Mooij
Hepatology (Baltimore, Md.)|January 12, 2012
Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemiaH Carlijne Hassing, Hans Mooij, Shuling Guo, et al.
Haematologica|November 2, 2018
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE studyAnton Hagenbeek, Hans Mooij, Josée Zijlstra, et al.
Pageof 1